Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA (NASDAQ: ACIU), a Switzerland-based developer of advanced immunotherapies, to obtain an exclusive global license for the company’s active immunotherapies that target toxic forms of amyloid beta (Abeta). This strategic partnership positions Takeda at the forefront of Alzheimer’s disease (AD) research and development.
Under the terms of the agreement, AC Immune will receive an upfront payment of USD 100 million, a potential option exercise fee, up to USD 2.1 billion in milestone payments, and potential sales royalties. The deal’s centerpiece is the investigational candidate ACI-24.060, a first-in-class active immunotherapy designed to induce an immune response against toxic Abeta species, potentially delaying or slowing the progression of AD.
ACI-24.060 is currently undergoing a Phase Ib/II clinical trial for prodromal AD and Down syndrome. AC Immune will be responsible for completing the trial, marking a significant step in the advancement of novel therapeutic approaches for Alzheimer’s disease.- Flcube.com
